{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"10.4","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The observed length of life from entry into the study to death or the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"OG000","title":"Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 5 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}